Shirley Wong
YOU?
Author Swipe
View article: Risk-based screening programmes for cancer diagnosis: A systematic review with narrative synthesis
Risk-based screening programmes for cancer diagnosis: A systematic review with narrative synthesis Open
Introduction: Risk-based screening (RBS) has emerged as a promising alternative to age-based cancer screening. However, evidence regarding real-world implementation outcomes remains fragmented. Thus, a systematic review was conducted to ev…
View article: Development of the International Classification of Functioning, Disability and Health (ICF) core set for stroke survivors in community-based rehabilitation settings in Hong Kong
Development of the International Classification of Functioning, Disability and Health (ICF) core set for stroke survivors in community-based rehabilitation settings in Hong Kong Open
The final core set reflects key dimensions of functioning relevant to stroke survivors receiving community-based rehabilitation services in Hong Kong.
View article: Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia
Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia Open
Objectives To explore Australian data on perioperative chemotherapy use and associated outcomes in muscle‐invasive bladder cancer (MIBC). Subjects and Methods An observational study of patients with MIBC treated with neoadjuvant chemothera…
View article: Transcriptomic predictors of prostate cancer recurrence following focal cryotherapy: a pooled analysis of phase II trial and prospective cohort data
Transcriptomic predictors of prostate cancer recurrence following focal cryotherapy: a pooled analysis of phase II trial and prospective cohort data Open
View article: A person-centred Healthier SG outcomes framework
A person-centred Healthier SG outcomes framework Open
View article: Temporal trends and outcomes of cardiac rehabilitation after acute coronary syndrome in an asian population
Temporal trends and outcomes of cardiac rehabilitation after acute coronary syndrome in an asian population Open
Background Acute Myocardial Infarction (AMI) is a leading cause of death in Singapore, and Centre-Based Cardiac Rehabilitation (CBCR) improves exercise capacity and mortality. However, data showing temporal trends and outcomes in Asian pop…
View article: Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study Open
Background: The extent of tumor shrinkage has been deemed a predictor of survival for advanced/metastatic renal cell carcinoma (RCC), a disease with historically poor survival. Objective: To perform an exploratory analysis of overall survi…
View article: Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: 1640. Acyclovir use in infants and children (0-18 years) in Pediatric hospitals in Australia and New Zealand for suspected herpes simplex virus infection
1640. Acyclovir use in infants and children (0-18 years) in Pediatric hospitals in Australia and New Zealand for suspected herpes simplex virus infection Open
Background Non-specific presentations of severe herpes simplex virus (HSV) infections and high risk of adverse outcomes have driven empiric acyclovir use. We therefore audited acyclovir prescribing in Australia and New Zealand for suspecte…
View article: Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia Open
The 5‐year survival rate of metastatic urothelial carcinoma (mUC) is estimated to be as low as 5%. Currently, systemic platinum‐based chemotherapy followed by avelumab maintenance therapy is the only first‐line treatment for mUC that has a…
View article: Supplementary Table 3 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Supplementary Table 3 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer Open
Adverse events
View article: Data from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Data from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer Open
Purpose:Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors. Here the pan-AKT kinase inhibitor afuresertib was given in combination with paclitaxel and carboplatin (PC) in patients with recurrent pla…
View article: Supplementary Table 1 from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Supplementary Table 1 from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation Open
PDF file - 66K, The pharmacokinetic parameters of BNC105 and BNC105P.
View article: Supplemental Table 2 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Supplemental Table 2 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer Open
Study treatment disposition
View article: Supplementary Figure 1 from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Supplementary Figure 1 from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation Open
PDF file - 191K
View article: Data from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Data from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation Open
Purpose: To determine the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and pharmacodynamic (PD) effects of BNC105P, an inhibitor of tubulin polymerization that has vascular disrupti…
View article: Supplementary Table 1 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Supplementary Table 1 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer Open
Summary of exposure to afuresertib, paclitaxel and carboplatin
View article: Supplementary Figure 1 from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Supplementary Figure 1 from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation Open
PDF file - 191K
View article: Supplementary Table 3 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Supplementary Table 3 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer Open
Adverse events
View article: Supplementary Table 1 from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Supplementary Table 1 from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation Open
PDF file - 66K, The pharmacokinetic parameters of BNC105 and BNC105P.
View article: Data from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Data from Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation Open
Purpose: To determine the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and pharmacodynamic (PD) effects of BNC105P, an inhibitor of tubulin polymerization that has vascular disrupti…
View article: Supplementary Table 1 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Supplementary Table 1 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer Open
Summary of exposure to afuresertib, paclitaxel and carboplatin
View article: Data from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Data from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer Open
Purpose:Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors. Here the pan-AKT kinase inhibitor afuresertib was given in combination with paclitaxel and carboplatin (PC) in patients with recurrent pla…
View article: Supplemental Table 2 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Supplemental Table 2 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer Open
Study treatment disposition
View article: Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study Open
View article: Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study Open
View article: Pretreatment of choriocarcinoma syndrome: a rare complication of metastatic germ cell tumours
Pretreatment of choriocarcinoma syndrome: a rare complication of metastatic germ cell tumours Open
A 27-year-old man newly diagnosed with metastatic testicular choriocarcinoma developed a large right perinephric haematoma secondary to a metastatic deposit in his right kidney. His presentation was also complicated by bilateral iliac veno…
View article: Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer Open
Introduction Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer (mCRPC). Access to these medications varies significantly worldwide. In Australia until recently, patients mu…
View article: Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy? Open
A 70-year-old man originally from Poland was referred to the hepatoma service for investigation of two liver lesions found during routine hepatocellular carcinoma (HCC) screening. Active medical history included both castrate sensitive met…
View article: Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer
Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer Open
Objectives To investigate the recent real‐world use of first‐generation antiandrogens (FGAs) in metastatic castration‐resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. Patients and Methods The electronic CRP…